Head-to-head · WeighScore
CoraDoc vs Invigor Medical
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 76.8/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Now Try Invigor, this platform advertises class-based GLP-1 plans; confirm your medicine and supply before accepting its starting price.
Before you choose
Before comparing the headline prices, the CoraDoc review and the Invigor Medical review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, CoraDoc vs Jyra Health and CoreAge Rx vs Invigor Medical compare each of them with another graded program, and the list of alternatives to CoraDoc ranks the programs closest to CoraDoc on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Gala Health review covers one graded close to these two, at 82.9/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoraDoc | Invigor Medical |
|---|---|---|
| WeighScore | 76.8/100 | 86.1/100 |
| Grade | C | B |
| Site position | #49 | #9 |
| Semaglutide | $924 upfront (12-month promotion, compounded) | Medication-specific quote unconfirmed; public GLP-1 treatment starts at $225. |
| Tirzepatide | $1,524 upfront (12-month promotion, compounded) | Medication-specific quote unconfirmed; public GLP-1 + GIP treatment starts at $350/month. |
| Coverage | Coverage not published | U.S. only; confirm medication-specific state availability |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- The 12-month promotion publishes the one-time payment for each medication
- The campaign lists clinician visits, medication, dose increases, shipping and supplies as included
- The weight-loss campaign advertises no automatic renewal for the annual offer
What to consider
- The lowest advertised monthly equivalents require paying for 12 months at once
- The refund policy describes a possible $100 clinical fee after medical ineligibility, despite the sales-page full-refund promise
- The pages checked did not name the dispensing pharmacy for an individual order
Strengths
- Consultation, medication and supplies advertised together
- Ordinary and microdose treatment listings are separately presented
- Clinical policy describes virtual consultation and relevant testing when needed
What to consider
- Current medication-specific dose and supply quote is unconfirmed
- Cancel new orders before the prescription enters the practitioner's queue
- Subscriptions need seven days’ notice before renewal processing; charges may occur early
- No universal GLP-1 lab panel, frequency or separate testing price published
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.